BeiGene, Ltd. (ONC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeiGene, Ltd. (ONC) has a cash flow conversion efficiency ratio of 0.042x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($201.94 Million) by net assets ($4.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ONC market cap overview for the company's overall valuation and market capitalisation.
BeiGene, Ltd. - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BeiGene, Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeiGene, Ltd. ranked by their cash flow conversion efficiency. Explore earnings quality score of BeiGene, Ltd. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Accton Technology Corp
TW:2345
|
0.377x |
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-B
|
0.077x |
|
JSW Steel Limited
NSE:JSWSTEEL
|
0.114x |
|
Intact Financial Corporation
TO:IFC
|
0.050x |
|
ABN Amro Group NV
AS:ABN
|
0.010x |
|
Zoetis Inc
NYSE:ZTS
|
0.174x |
|
EQT Corporation
NYSE:EQT
|
0.036x |
|
CHINA PAC.IN.GR.GDR/5 YC1
F:75CB
|
N/A |
Annual Cash Flow Conversion Efficiency for BeiGene, Ltd. (2013–2025)
The table below shows the annual cash flow conversion efficiency of BeiGene, Ltd. from 2013 to 2025. View ONC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.36 Billion | $1.13 Billion | 0.259x | +712.63% |
| 2024-12-31 | $3.33 Billion | $-140.63 Million | -0.042x | +87.10% |
| 2023-12-31 | $3.54 Billion | $-1.16 Billion | -0.327x | +4.17% |
| 2022-12-31 | $4.38 Billion | $-1.50 Billion | -0.341x | -61.22% |
| 2021-12-31 | $6.13 Billion | $-1.30 Billion | -0.212x | +36.16% |
| 2020-12-31 | $3.87 Billion | $-1.28 Billion | -0.332x | +56.75% |
| 2019-12-31 | $978.36 Million | $-750.27 Million | -0.767x | -145.53% |
| 2018-12-31 | $1.75 Billion | $-547.72 Million | -0.312x | -1775.86% |
| 2017-12-31 | $684.23 Million | $12.75 Million | 0.019x | +107.35% |
| 2016-12-31 | $352.91 Million | $-89.51 Million | -0.254x | +52.69% |
| 2015-12-31 | $74.32 Million | $-39.84 Million | -0.536x | -58.90% |
| 2014-12-31 | $25.77 Million | $-8.69 Million | -0.337x | -206.16% |
| 2013-12-31 | $-36.96 Million | $4.07 Million | -0.110x | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more